Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) have been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.50.

Several analysts have commented on the stock. Roth Capital set a $7.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 30th. Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Piper Jaffray Cos. reiterated a “sell” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, July 27th. Finally, FBR & Co reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.11% during mid-day trading on Thursday, hitting $1.86. The stock had a trading volume of 133,736 shares. BioDelivery Sciences International has a 12-month low of $1.70 and a 12-month high of $6.40. The stock’s market capitalization is $100.66 billion. The stock’s 50-day moving average price is $2.30 and its 200-day moving average price is $2.41.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.04. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.58 million. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The business’s revenue was up 200.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.39) EPS. On average, equities analysts anticipate that BioDelivery Sciences International will post ($1.22) EPS for the current fiscal year.

In other news, insider Niraj Vasisht sold 47,000 shares of the company’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $2.43, for a total value of $114,210.00. Following the sale, the insider now directly owns 73,081 shares of the company’s stock, valued at approximately $177,586.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Paolantonio Ernest Robert De sold 14,800 shares of the company’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $2.44, for a total transaction of $36,112.00. Following the completion of the sale, the chief financial officer now directly owns 14,866 shares in the company, valued at $36,273.04. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of BioDelivery Sciences International by 6.6% in the first quarter. JPMorgan Chase & Co. now owns 297,533 shares of the specialty pharmaceutical company’s stock worth $961,000 after buying an additional 18,533 shares during the last quarter. Bank of Montreal Can bought a new position in BioDelivery Sciences International during the second quarter valued at $1,648,000. Emerald Acquisition Ltd. bought a new position in BioDelivery Sciences International during the second quarter valued at $2,711,000. Janney Montgomery Scott LLC boosted its position in BioDelivery Sciences International by 12.0% in the second quarter. Janney Montgomery Scott LLC now owns 61,300 shares of the specialty pharmaceutical company’s stock valued at $294,000 after buying an additional 6,550 shares in the last quarter. Finally, Oxford Asset Management bought a new position in BioDelivery Sciences International during the second quarter valued at $536,000. 60.83% of the stock is currently owned by institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.